← All trials
NCT06659640
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 12, 2024
- Primary completion
- May 29, 2026
- Completion date
- May 29, 2026
- First posted
- Oct 26, 2024
- Last posted
- Nov 8, 2024
- Enrollment
- 32
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Alnylam PharmaceuticalsLead sponsor
- Alnylam PharmaceuticalsOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.